CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best CRISPR stocks to buy. Following CRISPR Therapeutics AG (NASDAQ:CRSP ...

There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific ...

Crispr investors have had a year to put aside so far, with the stock down 25%. Read more on CRSP's execution risks, high ...

CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025. ZUG, Switzerland and BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a ...

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Based on the average brokerage recommendation (ABR), CRISPR Therapeutics (CRSP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the ...

CRISPR Therapeutics (NASDAQ:CRSP) operates within the biotechnology segment, which remains active across key indices like the ...

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

CRISPR Therapeutics (NASDAQ:CRSP) has delayed a much-anticipated Phase 1 trial readout for CTX320, its in vivo gene editing ...

New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and ...